Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

• Post author:andrewkaretas
• Post published:December 9, 2024
• Post category:CD19/Scientific Publications

Continue ReadingAlpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases

• Post author:andrewkaretas
• Post published:November 18, 2024
• Post category:Dual/Scientific Publications

Continue ReadingPreclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases

ALLO-316 in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Updated Safety and Efficacy From the Phase 1 TRAVERSE Multicenter Study

• Post author:andrewkaretas
• Post published:November 7, 2024
• Post category:CD70/Scientific Publications

Continue ReadingALLO-316 in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Updated Safety and Efficacy From the Phase 1 TRAVERSE Multicenter Study

Cellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-cell Lymphoma^*

• Post author:andrewkaretas
• Post published:December 11, 2023
• Post category:CD19/Scientific Publications

*In collaboration with The University of Texas MD Anderson Cancer Center.

Continue ReadingCellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-cell Lymphoma^*

ALLO‑647 for Lymphodepletion in the Allogeneic CAR T Cell Setting: Safety Experience With ALLO‑501‌ /‌ 501A in Patients With Relapsed / Refractory Large B-Cell and Follicular Lymphomas

• Post author:andrewkaretas
• Post published:December 9, 2023
• Post category:ALLO-647/Scientific Publications

Continue ReadingALLO‑647 for Lymphodepletion in the Allogeneic CAR T Cell Setting: Safety Experience With ALLO‑501‌ /‌ 501A in Patients With Relapsed / Refractory Large B-Cell and Follicular Lymphomas

Preclinical Evaluation of Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR

• Post author:andrewkaretas
• Post published:November 2, 2023
• Post category:Dual/PLATFORM/Scientific Publications

Continue ReadingPreclinical Evaluation of Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR

Generation of Immune-Evasive Allogeneic CAR T Cells by Inactivation of the HLA Transcriptional Regulator RFX5 and Disruption of the Immune Synapse

• Post author:andrewkaretas
• Post published:November 2, 2023
• Post category:PLATFORM/Scientific Publications

Continue ReadingGeneration of Immune-Evasive Allogeneic CAR T Cells by Inactivation of the HLA Transcriptional Regulator RFX5 and Disruption of the Immune Synapse

Preclinical Development and Characterization of Allogeneic CAR T Cells Targeting Claudin18.2 Positive Tumors

• Post author:andrewkaretas
• Post published:November 2, 2023
• Post category:CLAUDIN/Scientific Publications

Continue ReadingPreclinical Development and Characterization of Allogeneic CAR T Cells Targeting Claudin18.2 Positive Tumors

Constitutive Turbodomains Enhance Expansion and Antitumor Activity of Allogeneic BCMA CAR T Cells in Preclinical Models

• Post author:andrewkaretas
• Post published:August 23, 2023
• Post category:BCMA/Scientific Publications

Continue ReadingConstitutive Turbodomains Enhance Expansion and Antitumor Activity of Allogeneic BCMA CAR T Cells in Preclinical Models

Presentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

• Post author:andrewkaretas
• Post published:June 15, 2023
• Post category:CD19/Scientific Publications

Continue ReadingPresentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)